2026 | Zeitschriftenaufsatz | Veröffentlicht | PUB-ID: 3017628
Ellebaek E, Weichenthal M, Gavrilova I, Asher N, Terheyden P, Utikal J, Suljeviić AJ, Pföhler C, Stojkovski I, Herbst RA, Ugurel S, Ruhlmann C, Berrocal A, Majem M, Dujovic B, Šabarić V, Duvancic T, Soria A, Donia M, Schmidt H, Friis RB, Gerasimov A, Shalamanova-Deleva G, Kontilev A, Lev-Ari S, Shapira R, Piccin L, Minisini A, Özdemir BC, Teterycz P, Mariuk-Jarema A, Ziogas D, Anastasopoulou A, Stefanou D, Gutiérrez L, Gebhardt C, Dummer R, Hauschild A, Mohr P, von Wasielewski I, Meier F, Haanen J, Svane IM, Ascierto PA, Mangana J, Rutkowski P, Gogas H, Bastholt L, Schadendorf D (2026)
Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study.
EJC Skin Cancer 4: 100773.
PUB |
DOI |
WoS